Advanced screening capabilities
- ATP-based cell-viability assay, with GR50 readouts
- 3D assay format, compatible with both 96- and 384-well plate layouts.
- Test up to 10 compounds in triplicate
- 10-point dose-response curves per drug
- A panel of 10 models, each designed to represent key bladder cancer drivers
Unlock the potential of bladder cancer research with our PDO screen panel